News
FDA issues warning letters to five unapproved GLP-1 websites
In a handful of strongly-worded warning letters, the FDA is cracking down on sales of unapproved peptides - even if they're labelled for research.
News
US puts $125m into personalised RNA therapy production
Federal funding from ARPA-H of $125m, awarded to five groups, is part of a drive to accelerate patient access to personalised genetic medicines.
News
Enhertu OK ends 10-year EU gap in frontline breast cancer
Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.
News
White House signs pricing deals with nine more pharmas
Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.
News
FDA clears Takeda, Protagonist's first-in-class PV drug
Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
